Buy our Recombinant hepatitis c virus Hepatitis C Virus Genotype 6 NS3 protein. Ab67974 is an active protein fragment produced in Escherichia coli and has been…
There are no specific protocols for Recombinant Hepatitis C Virus Hepatitis C Virus NS4 protein (ab49026). Please download our general protocols booklet
Protein target information for Chain A, Hepatitis C Virus Polymerase Ns5b (Bk) With Amide Bioisostere Thumb Site Inhibitor (Hepatitis C virus (isolate BK)). Find diseases associated with this biological target and compounds tested against it in bioassay experiments.
Recently, cell lifestyle systems producing hepatitis C virus particles (HCVcc) were developed. we developed serum-free culture systems producing high-titer single-density sf-HCVcc, showing similar biological properties as HCVcc. This methodology has the potential to advance HCV vaccine development and to facilitate biophysical studies of HCV. within the family. Due to a high degree of genetic heterogeneity, HCV has been categorized in 6 essential genotypes and several subtypes epidemiologically, differing in around 30% and 20% of their nucleotide and amino Vorinostat acidity sequence, [3 respectively,4]. Genotypes display important biological and clinical variations [5C10]. Serotypes Rabbit Polyclonal to 5-HT-2C. never have been defined; nevertheless, different genotypes and subtypes display differential level of sensitivity to neutralizing antibodies within sera of chronically contaminated patients also to monoclonal neutralizing antibodies with restorative potential [6,11C14]. The 9.6 kb HCV ...
TY - JOUR. T1 - Cutting edge. T2 - Identification of hepatitis C virus-specific CD8+ T cells restricted by donor HLA alleles following liver transplantation. AU - Rosen, Hugo R.. AU - Hinrichs, David J.. AU - Leistikow, Rachel L.. AU - Callender, Glenda. AU - Wertheimer, Anne M.. AU - Nishimura, Michael I.. AU - Lewinsohn, David M.. PY - 2004/11/1. Y1 - 2004/11/1. N2 - By necessity, human liver transplantation is performed across HLA barriers. As a result, intracellular infection of the allograft presents a unique immunologic challenge for the recipients immune system. In this study, we describe the presence of HLA-A2-restricted, hepatitis C virus (HCV)-specific CD8+ T cells in liver transplant recipients in whom the allograft is HLA-A2 positive and the recipient is HLA-A2 negative. These memory-effector T cells are recipient derived and recognize HCV peptide uniquely in the context of HLA-A2. Furthermore, these cells were absent before the transplant, suggesting that the allograft is capable ...
Persistent infection with hepatitis C virus (HCV) often causes chronic hepatitis, and then shows a high rate of progression to liver cirrhosis and hepatocellular carcinoma. To clarify the mechanism of the persistent HCV infection is considered to be important for the discovery of new target(s) for the development of anti-HCV strategies. In the present study, we found that the expression level of annexin A1 (ANXA1) in human hepatoma cell line Li23-derived D7 cells was remarkably lower than that in parental Li23 cells, whereas the susceptibility of D7 cells to HCV infection was much higher than that of Li23 cells. Therefore, we hypothesized that ANXA1 negatively regulates persistent HCV infection through the inhibition of viral RNA replication. The results revealed that HCV production was significantly inhibited without a concomitant reduction in the amount of lipid droplets in the D7 cells stably expressing exogenous ANXA1. Further, we demonstrated that ANXA1 negatively regulated the step of ...
Interferon alpha (IFN-α) is the key component of the therapy for hepatitis C virus (HCV) infection. IFN-α exerts anti-HCV activity by targeting certain signaling pathways. Using infectious HCV culture system in human hepatoma Huh7.5.1 cells, we analyzed functional relevance of extracellular signal-regulated kinase (ERK) pathway for IFN-α-mediated anti-HCV activity. IFN-α treatment resulted in activation of ERK pathway by increasing phosphorylation of c-Raf, MEK, and ERK1/2 in Huh7.5.1 cells, whereas HCV impaired such activation. IFN-α-dependent ERK1/2 phosphorylation was blocked by MEK inhibitor U0126. Pharmacological inhibition of ERK1/2 by U0126 or siRNA-mediated knockdown of ERK1/2 resulted in suppressive effects on HCV RNA levels and expression of HCV nonstructural protein 3 and envelope protein 2, establishing an important role for ERK pathway in HCV replication. Moreover, induction of a set of antiviral genes by IFN-α was enhanced in HCV-infected Huh7.5.1 cells due to the ERK1/2 knockdown,
Prices are in US dollars.. These products are for laboratory research purposes only, not for any human or animal diagnostic or therapeutic use.. All site content © 2017 Cell Sciences, Inc.. ...
Gentaur molecular products has all kinds of products like :search , AbD \ RECOMBINANT HEPATITIS C, Product Type Recombinant Protein, Specificity HEPATITIS C, Target Species Viral, Host N_A, Format Rec. Protein, Isotypes , Applications E, Clone \ 0100-0410 for more molecular products just contact us
Gentaur molecular products has all kinds of products like :search , AbD \ RECOMBINANT HEPATITIS C, Product Type Recombinant Protein, Specificity HEPATITIS C, Target Species Viral, Host N_A, Format Rec. Protein, Isotypes , Applications E, Clone \ 0100-0411 for more molecular products just contact us
Download Free Full-Text of an article THE DIFFERENCES IN GENE EXPRESSION PROFILE INDUCED BY GENOTYPE 1B HEPATITIS C VIRUS CORE ISOLATED FROM LIVER TUMOR AND ADJACENT NON-TU-MORAL TISSUE
The present invention discloses nucleic acid sequences which encode infectious hepatitis C viruses and the use of these sequences, and polypeptides encoded by all or part of these sequences, in the development of vaccines and diagnostics for HCV and in the development of screening assays for the identification of antiviral agents for HCV.
Hepatitis C virus, illustration. Hepatitis C is most commonly spread by blood contact, through blood transfusions or the sharing of infected needles. It causes inflammation of the liver with jaundice and flu-like symptoms. There is currently no vaccine for hepatitis C. - Stock Image F019/2553
TY - JOUR. T1 - Intracellular proton conductance of the hepatitis C virus p7 protein and its contribution to infectious virus production. AU - Wozniak, Ann L.. AU - Griffin, Stephen. AU - Rowlands, David. AU - Harris, Mark. AU - Yi, Min Kyung. AU - Lemon, Stanley M.. AU - Weinman, Steven A.. PY - 2010/9/1. Y1 - 2010/9/1. N2 - The hepatitis C virus (HCV) p7 protein is critical for virus production and an attractive antiviral target. p7 is an ion channel when reconstituted in artificial lipid bilayers, but channel function has not been demonstrated in vivo and it is unknown whether p7 channel activity plays a critical role in virus production. To evaluate the contribution of p7 to organelle pH regulation and virus production, we incorporated a fluorescent pH sensor within native, intracellular vesicles in the presence or absence of p7 expression. p7 increased proton (H+) conductance in vesicles and was able to rapidly equilibrate H+ gradients. This conductance was blocked by the viroporin ...
DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of ...
Goat polyclonal antibody raised against recombinant human hepatitis C virus. Recombinant protein corresponding to human hepatitis C virus. (PAB14675) - Products - Abnova
A better understanding of natural variation in neutralization resistance and fitness of diverse hepatitis C virus (HCV) envelope (E1E2) variants will be critical to guide rational development of an HCV vaccine. This work has been hindered by inadequate genetic diversity in viral panels and by a lack of standardization of HCV entry assays. Neutralization assays generally use lentiviral pseudoparticles expressing HCV envelope proteins (HCVpp) or chimeric full-length viruses that are replication competent in cell culture (HCVcc). There have been few systematic comparisons of specific infectivities of E1E2-matched HCVcc and HCVpp, and to our knowledge, neutralization of E1E2-matched HCVpp and HCVcc has never been compared using a diverse panel of human broadly neutralizing monoclonal antibodies (bNAbs) targeting distinct epitopes. Here, we describe an efficient method for introduction of naturally occurring E1E2 genes into a full-length HCV genome, producing replication-competent chimeric HCVcc. We
Hepatitis C virus (HCV) infection in humans is remarkably efficient in establishing viral persistence, leading to the development of liver cirrhosis and hepatocellular carcinoma. T cell responses have been reported to play a pivotal role in controlling HCV infection. However, HCV-specific T cell responses are significantly impaired in chronic HCV patients. This suggests that HCV may employ numerous mechanisms to counteract or possibly suppress the host T cell responses. Our laboratory is mainly focused on two inter-related arenas of biomedical research to elucidate the mechanism of HCV-mediated inhibition of T cell responses. Our research program involves both human and mouse studies. A better understanding of HCV-mediated immune regulation will provide a basis for the rational design of HCV therapeutics. Interaction of HCV-infected hepatocytes with NK cells and DC. The primary site of HCV replication occurs within hepatocytes in the liver. As a result of liver enodothelial cells perforated by ...
Since its initial identification in St. Petersburg, Russia, the recombinant hepatitis C virus (HCV) 2k/1b has been isolated from several countries throughout Eurasia. The 2k/1b strain is the only recombinant HCV to have spread widely, raising questions about the epidemiological background in which it first appeared. In order to further understand the circumstances by which HCV recombinants might be formed and spread, we estimated the date of the recombination event that generated the 2k/1b strain using a Bayesian phylogenetic approach. Our study incorporates newly isolated 2k/1b strains from Amsterdam, The Netherlands, and has employed a hierarchical Bayesian framework to combine information from different genomic regions. We estimate that 2k/1b originated sometime between 1923 and 1956, substantially before the first detection of the strain in 1999. The timescale and the geographic spread of 2k/1b suggest that it originated in the former Soviet Union at about the time that the worlds first centralized
Hepatitis C Virus NS3山羊多克隆抗体(ab21124)经WB, ELISA, ICC/IF实验严格验证,被4篇文献引用。所有产品均提供质保服务,中国75%以上现货。
Merani, S., Petrovic, D., James, I., Chopra, A., Cooper, D., Freitas, E., Rauch, A., di Iulio, J., John, M., Lucas, M., Fitzmaurice, K., McKiernan, S., Norris, S., Kelleher, D., Klenerman, P. and Gaudieri, S. (2011), Effect of immune pressure on hepatitis C virus evolution: Insights from a single-source outbreak. Hepatology, 53: 396-405. doi: 10.1002/hep.24076 ...
Sigma-Aldrich offers abstracts and full-text articles by [Dorothee A Vogt, Grégory Camus, Eva Herker, Brian R Webster, Chia-Lin Tsou, Warner C Greene, Tien-Sze Benedict Yen, Melanie Ott].
Hepatitis C Virus NS5B protein antibody for WB. Anti-Hepatitis C Virus NS5B protein pAb (GTX131274) is tested in Hepatitis C virus samples. 100% Ab-Assurance.
The primary objective of this trial is to compare the efficacy of boceprevir (SCH 503034) 800 mg three times a day (TID) orally (PO) in combination with peginterferon alfa-2b (PegIFN-2b) 1.5 µg/kg weekly (QW) subcutaneously (SC) plus weight-based dosing (WBD) of ribavirin (RBV) (600 mg/day to 1400 mg/day) PO to therapy with PegIFN-2b + RBV alone in adult participants coinfected with human immunodeficiency virus (HIV) and previously untreated chronic hepatitis C virus (HCV) genotype 1.. Boceprevir is a potent, orally administered, novel serine protease inhibitor, specifically designed to inhibit the HCV nonstructural protein 3 (NS3) protease and, thereby, inhibit viral replication in HCV-infected host cells. The mechanism of inhibition represents a new mechanism of action compared to both interferon alfa and ribavirin. Based on previous experience with PegIFN-2b and RBV in combination with boceprevir in the HCV-monoinfected population, this combination treatment is expected to provide ...
The primary objective of this trial is to compare the efficacy of boceprevir (SCH 503034) 800 mg three times a day (TID) orally (PO) in combination with peginterferon alfa-2b (PegIFN-2b) 1.5 µg/kg weekly (QW) subcutaneously (SC) plus weight-based dosing (WBD) of ribavirin (RBV) (600 mg/day to 1400 mg/day) PO to therapy with PegIFN-2b + RBV alone in adult participants coinfected with human immunodeficiency virus (HIV) and previously untreated chronic hepatitis C virus (HCV) genotype 1.. Boceprevir is a potent, orally administered, novel serine protease inhibitor, specifically designed to inhibit the HCV nonstructural protein 3 (NS3) protease and, thereby, inhibit viral replication in HCV-infected host cells. The mechanism of inhibition represents a new mechanism of action compared to both interferon alfa and ribavirin. Based on previous experience with PegIFN-2b and RBV in combination with boceprevir in the HCV-monoinfected population, this combination treatment is expected to provide ...
Hepatitis C Virus NS4A protein antibody [497] for ELISA, WB. Anti-Hepatitis C Virus NS4A protein mAb (GTX19052) is tested in Hepatitis C virus samples. 100% Ab-Assurance.
Isolation and self-replication of infectious HCV has been a difficult task. However, this is needed for the purposes of developing rational drugs and for the analysis of the natural virus. Our recent report of an in vitro system for the isolation of human HCV from infected patients and their replication in tissue culture addresses this challenge. At California Institute of Molecular Medicine several isolates of HCV, called CIMM-HCV, were grown for over three years in cell culture. This is a report of the analysis of CIMM-HCV isolates for subtypes and quasispecies using a 269 bp segment of the 5UTR. HCV RNA from three patients and eleven CIMM-HCV were analyzed for this purpose. All isolates were essentially identical. Isolates of HCV from one patient were serially transmitted into fresh cells up to eight times and the progeny viruses from each transmission were compared to each other and also to the primary isolates from the patients serum. Some isolates were also transmitted to different cell types,
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
As a member of the wwPDB, the RCSB PDB curates and annotates PDB data according to agreed upon standards. The RCSB PDB also provides a variety of tools and resources. Users can perform simple and advanced searches based on annotations relating to sequence, structure and function. These molecules are visualized, downloaded, and analyzed by users who range from students to specialized scientists.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. ...
Thank you for sharing this Journal of Virology article.. NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.. ...
Previous studies documented that long-term hepatitis C virus (HCV) replication in human hepatoma Huh-7.5 cells resulted in viral fitness gain, expansion of the mutant spectrum, and several phenotypic alterations. In the present work, we show that mutational waves (changes in frequency of individual mutations) occurred continuously and became more prominent as the virus gained fitness. They were accompanied by an increasing proportion of heterogeneous genomic sites that affected 1 position in the initial HCV population and 19 and 69 positions at passages 100 and 200, respectively. Analysis of biological clones of HCV showed that these dynamic events affected infectious genomes, since part of the fluctuating mutations became incorporated into viable genomes. While 17 mutations were scored in 3 biological clones isolated from the initial population, the number reached 72 in 3 biological clones from the population at passage 200. Biological clones differed in their responses to antiviral inhibitors, ...
Chronic hepatitis C virus (HCV) infection is characterized by persistent high-level viremia and defective cellular immunity, including a lack of functional HCV-specific CD4+ T cells. We previously described an exceptional period of viral control that occurs in some chronically infected women after childbirth. Here, we investigated whether reduced HCV replication after pregnancy is associated with recovery of CD4+ T cell immunity. Class II tetramer analysis revealed significantly greater frequencies of circulating HCV-specific CD4+ T cells at 3 months postpartum in women with concurrent declines in viremia compared with those with stable viremia. These HCV-specific CD4+ T cells had an effector-memory phenotype. Inhibitory coreceptor expression on these cells corresponded to the degree of viral control. Circulating CD4+ T cells produced IL-2 and IFN-γ after HCV antigen stimulation, demonstrating Th1 functionality. These data provide direct evidence that the profound loss of HCV-specific CD4+ T ...
Resistance mutations to hepatitis C virus (HCV) nonstructural protein 3 (NS3) protease inhibitors in ,1% of the viral quasispecies may still allow ,1000-fold viral load reductions upon treatment, consistent with their reported reduced replicative fitness in vitro. Recently, however, an R155K protease mutation was reported as the dominant quasispecies in a treatment-naïve individual, raising concerns about possible full drug resistance. To investigate the prevalence of dominant resistance mutations against specifically targeted antiviral therapy for HCV (STAT-C) in the population, we analyzed HCV genome sequences from 507 treatment-naïve patients infected with HCV genotype 1 from the United States, Germany, and Switzerland. Phylogenetic sequence analysis and viral load data were used to identify the possible spread of replication-competent, drug-resistant viral strains in the population and to infer the consequences of these mutations upon viral replication in vivo. Mutations described to ...
We have previously reported the isolation of HCV from infected patients and in vitro replication of these isolates [10]. A molecular analysis of CIMM-HCV for possible subtypes and quasispecies was recently performed which showed that the isolated HCV had only minor sequence changes compared to patient HCV [11].. A patient with unique deletions is the subject of this study. This patient had not yet undergone therapy, and therefore the deletions found in the patient were not induced by treatment. Deletions of up to 18 bases in the 5UTR, along with additions of up to 40 bases have previously been reported [12], and deletions of up to 2 kb have been found in the protein coding region of HCV [13]. The deletions of 113 or 116 bp in patient 313 were limited to the region between two strings of Cs in the 5UTR. Domains IIIa through IIIc, which are missing in these deletions, are thought to be bound by the right leg of eIF3 [14]. Otto et al. [15] crosslinked a IIIa to IIIc domain deletion named ...
During hepatitis C virus (HCV) infection broadly neutralizing antibody (bNAb) responses targeting E1E2 envelope glycoproteins are generated in many individuals. It is unclear if these antibodies play a protective or a pathogenic role during chronic infection. In this study, we investigated whether bNAb responses in individuals with chronic infection were associated with differences in clinical presentation. Patient-derived purified serum IgG was used to assess the breadth of HCV E1E2 binding and neutralization activity of HCV pseudoparticles. Two panels were compared, bearing viral envelope proteins representing either an inter-genotype or an intra-genotype (gt) 1 group. We found that HCV viral load was negatively associated with strong cross-genotypic E1E2 binding (P=0.03). Overall we observed only modest correlation between total E1E2 binding and neutralizing ability. The breadth of inter-genotype neutralization did not correlate with any clinical parameters, however, analysis of individuals ...
Hepatitis C virus (HCV) infection afflicts approximately 170 million people worldwide and chronic virus infection in these individuals is a significant cause of...
The first NS3/4A hepatitis C virus (HCV) protease inhibitors telaprevir and boceprevir were approved in 2011,and both NS5A and NS5B polymerase inhibitors were launched. Recently, direct-acting antivirals (DAAs) have had a major impact on patients infected with Hepatitis C virus (HCV). HCV DAAs are highly effective antivirals with fewer side effects. DAAs have been developed for treatment of HCV infection in combination with PEG-IFNα/RBV as well as in IFN-free regimens. However, some drug resistance mutations occur when a single oral DAA is used for treatment, which indicates that there is a low-frequency drug resistance mutation in HCV patients before the application of antiviral drugsOur research showed that natural resistance to HCV DAAs was found in treatment-naïve CHC patients and that the drug resistance mutation rates differ in various HCV genotypes ...
Successful hepatitis C virus (HCV) treatment is defined as the absence of viremia 6 months after therapy cessation. We previously reported that trace amounts of HCV RNA, below the sensitivity of the standard clinical assay, can reappear sporadically in treatment responders. Here, we assessed the infectivity of this RNA and infused 3 chimpanzees sequentially at 9-week intervals with plasma or PBMCs from patients who tested positive for trace amounts of HCV RNA more than 6 months after completing pegylated IFN-α/ribavirin therapy. A fourth chimpanzee received HCV RNA-negative plasma and PBMCs from healthy blood donors. The 3 experimental chimpanzees, but not the control chimpanzee, generated HCV-specific T cell responses against nonstructural and structural HCV sequences 6-10 weeks after the first infusion of patient plasma and during subsequent infusions. In 1 chimpanzee, T cell responses declined, and this animal developed high-level viremia at week 27. Deep sequencing of HCV demonstrated ...
Successful hepatitis C virus (HCV) treatment is defined as the absence of viremia 6 months after therapy cessation. We previously reported that trace amounts of HCV RNA, below the sensitivity of the standard clinical assay, can reappear sporadically in treatment responders. Here, we assessed the infectivity of this RNA and infused 3 chimpanzees sequentially at 9-week intervals with plasma or PBMCs from patients who tested positive for trace amounts of HCV RNA more than 6 months after completing pegylated IFN-α/ribavirin therapy. A fourth chimpanzee received HCV RNA-negative plasma and PBMCs from healthy blood donors. The 3 experimental chimpanzees, but not the control chimpanzee, generated HCV-specific T cell responses against nonstructural and structural HCV sequences 6-10 weeks after the first infusion of patient plasma and during subsequent infusions. In 1 chimpanzee, T cell responses declined, and this animal developed high-level viremia at week 27. Deep sequencing of HCV demonstrated ...
The treatment of patients with HCV genotype 3 has remained a clinical challenge in the era of direct-acting antiviral agents. Patients with HCV genotype 3, especially those who have not had a response to previous treatment and those with cirrhosis, have relatively poor rates of response to standard treatment with sofosbuvir-ribavirin. In the ALLY-3 phase 3 trial, among patients with HCV genotype 3 who received 12 weeks of sofosbuvir with the NS5A inhibitor daclatasvir, a sustained virologic response was reported in 90% of previously untreated patients and in 86% of previously treated patients. However, the response rate fell to 63% among patients with compensated cirrhosis.16 The addition of peginterferon to sofosbuvir-ribavirin has been shown to improve outcomes but at the expense of greater toxic effects and the exclusion of patients who have unacceptable side effects from interferon.17 In this context, the finding that the rates of sustained virologic response in every subgroup of patients ...
p7 protein is a small protein encoded by Hepatitis C virus (HCV) that functions as an ion channel in planar lipid bilayers. The function of p7 is vital for the virus life cycle. In this study, the p7 protein of genotype 2a (strain JFH1; the only strain that replicates and produces virus progeny in vitro) was tagged with either an enhanced green fluorescent protein (eGFP) or a haemagglutinin (HA) epitope to facilitate tracking of the protein in the intracellular environment. The tagged viral polyprotein was expressed transiently in the cells after transfection with the recombinant RNA transcripts. Confocal microscopy revealed that the tagged p7 protein was localized in the endoplasmic reticulum (ER) but not associated with mitochondria. Immunoelectron microscopy confirmed the p7 localization data and, moreover, showed that intracellular virus-like particles formed in the cells transfected with the wild-type, but not the recombinant, transcripts. Following a few passages of the transfected cells, the
Quantification of the 5 noncoding region of the genomic and antigenomic HCV RNA strands was done using a strand-specific real-time RT-PCR, with use of the thermostable enzyme Tth for the synthesis of cDNA at a high temperature. Thus, for the amplification of the genomic HCV RNA strand, cDNA was generated in 20 L of reaction mixture that contained the total RNA extracted from 200 uL of serum or 0.5 ug of total RNA from liver specimens or PBMC samples, 50 pmol/L antisense primer UTRLC2 (5-CAAGCACCCTATCAGGCAGT-3), 1 mmol/L MnCl2, 200 umol/L each deoxynucleotide triphosphate, 1X RT buffer (Applied Biosystems), and 5 U of Tth (Applied Biosystems). After 20 min at 65 C, the RT activity was inactivated by Mn2+ chelation with 8 uL of the 10X chelating buffer (Applied Biosystems), followed by heating at 95 C for 30 min. For amplification of antigenomic HCV RNA, cDNA was synthesized under the same conditions by the addition of 50 pmol/L sense primer UTRLC1 (5-CTTCACGCAGAAAGCGTCTA-3). Real-time PCR was ...
The HCV replication complex. After clathrin-mediated endocytosis, fusion of HCV with cellular membranes, and uncoating the viral nucleocapsid, the single-stranded positive-sense RNA genome of the virus of approximately 9600 nucleotides is released into the cytoplasm to serve as a messenger RNA for the HCV polyprotein precursor. The HCV genome contains a single large open reading frame encoding for a polyprotein of approximately 3100 amino acids. The translated section of the HCV genome is flanked by the strongly conserved HCV 3′ and 5′ untranslated regions (UTR). The 5′ UTR is comprised of four highly structured domains forming the internal ribosome entry site (IRES), which is a virus-specific structure to initiate HCV mRNA translation. From the initially translated polyprotein, the structural HCV protein core (C) and envelope 1 and 2 (E1, E2); p7; and the six nonstructural HCV proteins NS2, NS3, NS4A, NS4B, NS5A and NS5B, are processed by both viral and host proteases. The core protein ...
© 2014 Wiley Periodicals, Inc. HCV strains belonging to genotype 4 may be gaining endemicity across Continental Europe but the extent of their spread in the United Kingdom is unknown. Sera referred from patients attending hospitals in England between 2004 through 2008 were characterised. A total of 243 sera carried HCV genotype 4. The most common subtypes were 4a (33%) and 4d (35%). Compared to patients infected by 4d, those infected by 4a were 20 times more likely to be Middle Eastern than English, and those infected by non-4a/4d were older, tended to be female, and 50 or 12 times more likely to be Middle Eastern or South Asian, respectively, than English. Persons infected by 4d tended to be English rather than Middle Eastern or South Asian. One group of 4d strains clustered with strains reported from persons in Europe engaged in male homosexual activity. Surveillance of trends in the importation and subsequent spread of HCV genotype 4 and its subtypes is advocated. J. Med. Virol. 87:417-423, 2015.
1CU1: Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase.
Priming and stimulation of hepatitis C virus-specific CD4+ and CD8+ T cells against HCV antigens NS4, NS5a or NS5b from HCV-naive individuals: implications for prophylactic vaccine. Wen Li; Deepa K. Krishnadas; Rakesh Kumar; D. Lorne J. Tyrrell; Babita Agrawal // International Immunology;Jan2008, Vol. 20 Issue 1, p89 Hepatitis C virus (HCV) is a devastating human pathogen, yet there is no vaccine available for this virus. From studies with acute or chronic HCV-infected humans and chimpanzees, T-cell responses against HCV-derived conserved non-structural antigens have been correlated with viral clearance. In... ...
Sigma-Aldrich offers abstracts and full-text articles by [Daniel M Forton, Peter Karayiannis, Nadiya Mahmud, Simon D Taylor-Robinson, Howard C Thomas].
It remains difficult to achieve high sustained response rates (SVRs) in chronic hepatitis patients coinfected with human immunodeficiency virus (HIV). The aim of this study was to perform a meta-analy
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.